Rockwell Medical Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities

Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI) has launched a Convenience Pack for its hemodialysis concentrate products CitraPure®, RenalPure®, and SteriLyte®. The pack includes two 1-gallon pre-mixed containers, offering easier handling and streamlined workflow for home hemodialysis patients, caregivers, and acute dialysis facilities.

This new packaging option aims to support the growing trend of at-home dialysis treatments, which can reduce costs and improve patient experience. Rockwell Medical provides FDA-regulated products, reliable delivery services, and adheres to ISO 13485 certification, cGMP, and AAMI standards. The company manufactures a full suite of hemodialysis products, including concentrates, powders, liquids, and accessories.

Positive

• Launch of Convenience Pack for easier handling in home hemodialysis and acute care settings
• Supports growing trend of at-home dialysis treatments, potentially expanding market reach
• FDA-regulated products and ISO 13485 certification demonstrate quality assurance

Negative

• None.

Medical Device Analyst

Rockwell Medical's launch of the Convenience Pack for hemodialysis concentrates is a strategic move to capitalize on the growing trend of home dialysis. This product innovation addresses key challenges in home and acute care settings:

• Improved ergonomics and accessibility for patients and caregivers
• Streamlined workflow for healthcare providers
• Potential for cost reduction in dialysis treatments

While this launch is a positive step, its immediate financial impact may be The real value lies in Rockwell's positioning for future growth in the home dialysis market. Investors should monitor adoption rates and any subsequent increase in market share to gauge the long-term success of this initiative.

Healthcare Market Analyst

Rockwell Medical's Convenience Pack launch aligns with the broader healthcare trend of shifting treatments from clinical to home settings. This move could potentially:

• Increase Rockwell's competitiveness in the growing home hemodialysis market
• Improve patient satisfaction and adherence to treatment regimens
• Reduce healthcare system costs associated with in-center dialysis

However, the success of this product will depend on factors such as reimbursement policies, patient education and healthcare provider adoption. Investors should watch for partnerships with home dialysis equipment manufacturers and changes in Medicare policies that could accelerate the shift to home-based care.

Financial Analyst

While the launch of the Convenience Pack is a positive development for Rockwell Medical, its financial impact may take time to materialize. Key considerations for investors include:

• Potential for increased market share in the growing home hemodialysis segment
• Possible margin improvements if the new packaging commands a premium price
• Initial costs associated with production and marketing of the new product format

Rockwell's focus on quality (ISO 13485 Certification, cGMP adherence) is important for maintaining its position in a highly regulated market. Investors should monitor upcoming quarterly reports for signs of revenue growth and any changes in the sales mix attributed to this new product offering.

Two 1-gallon pre-mixed containers of hemodialysis concentrates products CitraPure, RenalPure, or SteriLyte offer easier handling and streamlined workflow for patients, caregivers and healthcare providers

WIXOM, Mich.--(BUSINESS WIRE)-- Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has launched a Convenience Pack, which includes two 1-gallon pre-mixed containers of one of the Company's hemodialysis concentrate products CitraPure^®, RenalPure^®, or SteriLyte^®, offering a number of advantages for home patients and acute facilities.

"We are excited to offer home hemodialysis patients and acute care facilities a new, more ergonomic packaging option that is more accessible and easier to handle," said Tim Chole, Chief Commercial Officer at Rockwell Medical. "There is a patient-centric movement to drive dialysis treatments into the home to reduce the cost and complexity of dialysis treatments, all the while transforming the dialysis experience for patients. Rockwell is excited to become a critical player in the at-home market to support hemodialysis patients and their journey to take control over their time and treatments."

Rockwell Medical provides the hemodialysis community with high-quality products regulated by the U.S. Food and Drug Administration (FDA), reliable delivery services, and a robust Quality Management System. The Company is ISO 13485 Certified and adheres to current Good Manufacturing Practices (cGMP) and Association for Advancement of Medical Instrumentation (AAMI) standards. Rockwell manufactures a full suite of products including Citric Acid Concentrate Powders and Liquids; Acetic Acid Concentrate Powders and Liquids; Bicarbonate Concentrate Powders and Liquids; and Product Mixer, Cleaners and Accessories. For more information about Rockwell Medical's Convenience Pack, or to learn how you can include a Convenience Pack on your next order, please contact Rockwell Medical's Sales Team at www.rockwellmed.com/contact.

About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States and has the vision of becoming the leading global supplier of hemodialysis concentrates. Certified as a Great Place to Work^® in 2023 and 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions^™. For more information, visit www.RockwellMed.com.

Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are on track,” “are resolute in our vision,” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. There can be no assurance that Rockwell Medical will become the leading global supplier of hemodialysis concentrates. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240807907576/en/

Heather R. Hunter

SVP, Chief Corporate Affairs Officer

(248) 432-1362

IR@RockwellMed.com

Source: Rockwell Medical, Inc.

FAQ

What is Rockwell Medical's new Convenience Pack for hemodialysis products?

Rockwell Medical's Convenience Pack includes two 1-gallon pre-mixed containers of hemodialysis concentrate products (CitraPure, RenalPure, or SteriLyte), designed for easier handling and streamlined workflow in home hemodialysis and acute care settings.

How does the Convenience Pack benefit home hemodialysis patients and acute facilities?

The Convenience Pack offers more ergonomic packaging that is more accessible and easier to handle, supporting the trend of at-home dialysis treatments by reducing cost and complexity while improving the patient experience.

What quality standards does Rockwell Medical (RMTI) adhere to for its hemodialysis products?

Rockwell Medical adheres to FDA regulations, is ISO 13485 Certified, and follows current Good Manufacturing Practices (cGMP) and Association for Advancement of Medical Instrumentation (AAMI) standards.

What types of hemodialysis products does Rockwell Medical (RMTI) manufacture?

Rockwell Medical manufactures a full suite of products including Citric Acid Concentrate Powders and Liquids, Acetic Acid Concentrate Powders and Liquids, Bicarbonate Concentrate Powders and Liquids, and Product Mixer, Cleaners and Accessories.